New process to disrupt hepatitis C virion production developedMarch 22nd, 2008 - 2:47 pm ICT by admin
Washington, Mar 22 (ANI): Researchers at Scripps Florida have developed a method to disrupt the production of hepatitis C virion (HCV)a significant human pathogen, infecting more than three percent of the worlds populationpaving the way for development of new therapies.
The method was developed by Timothy Tellinghuisen, an assistant professor in the Department of Infectology at Scripps Florida, and his colleagues who used mutations of the viral NS5A phosphoprotein to disrupt virus particle production at an early stage of assembly.
Since a long time, NS5A has been proposed as a regulator of events in the HCV life cycle, however, its actual mechanism was not known clearly.
The interesting thing about this mutant is that while it triggers totally normal RNA replication, it causes severe defects in the output of infectious virusin fact, it releases no infectious virus that we can detect. And though this discovery isnt a cure for HCV, it is an important research tool that stops the assembly pathway. Total disruption of the replication process would be a cure for the disease, he adds, and thats the teams long-term goal, said Tellinghuisen.
HCV infection is pandemic in nature and is almost five to seven times more prevalent than HIV. HCV occurs when blood from an infected person enters the body of someone who is not infected. Most new HCV infections are due to illegal drug injections and sharing needles. But, those who had blood transfusions prior to blood donor screening in 1991, healthcare workers who had needle stick accidents, and hemodialysis patients are also at risk for developing HCV infection.
Mainly, the virus infects the liver, and following many decades of virus reproduction it leads to serious disease such as hepatitis (liver inflammation), cirrhosis (liver scarring), and carcinoma (liver cancer). Finally, HCV infection destroys the liver, resulting in death. Attempts at curing HCV infections with drug therapy have been only marginally successful.
The researchers focused on NS5A for understanding the regulation of events used by the virus to assemble infectious copies of itself and exit the cell. NS5A is a three-domain protein, i.e. it is comprised of three closely folded regions almost 50 to 300 amino acids in length. The requirement of domains I and II for RNA replication is well documented. However, NS5A domain III is not required for RNA replication, and the function of this region in the HCV life cycle is unknown.
The researchers used standard molecular biology to remove a coding sequence corresponding to roughly 15 amino acids from domain III of NS5A. Later, they generated a clone of the virus, transcribed the RNA from that clone, and purified the RNA. This RNA, which is directly infectious, was then transfixed into a liver cell line where it produced all the HCV proteins that are encoded by that RNA genome.
Those proteins assemble in the cell to make a structure called a replicase that then copies the viral RNAWe measured that RNA accumulation and observed no defect in RNA replication, but found, surprisingly, that no infectious viral particles were released from the cells, explained Tellinghuisen.
It was also found that no viral RNA and no nucleocapsid protein are released from cells, indicating that an early event in virus assembly had been affected.
Through genetic mapping and biochemical analyses it was shown that their deletion altered a phosphorylation signal controlling the switch from RNA replication to virus particle assembly. This signal was ascribed to the activity of a cellular kinase that when inhibited by genetic or chemical means led to a reduction in infectious virus production without altering HCV RNA replication.
These data provide the first evidence for a function of domain III of NS5A and implicate NS5A as an important regulator of the RNA replication and virion assembly of HCV. The ability to uncouple virus production from RNA replication may be useful in understanding HCV assembly and may become therapeutically important, said Tellinghuisen.
The study is published in the latest issue of the journal PLoS Pathogens. (ANI)
- Hepatitis C virus infection linked to fat enzyme in liver cells - Oct 11, 2010
- Hepatitis C vaccine undergoing trials - Aug 16, 2012
- New therapy could help beat Hepatitis C virus - Jan 17, 2012
- First vaccine for viral hepatitis C may soon become a reality - Apr 02, 2011
- Interfering genes protect monkeys from lethal Ebola virus post-exposure - May 30, 2010
- Protein key to hepatitis C virus replication identified - Aug 15, 2009
- Study finds enzyme that aids in the release of HIV particles - Mar 12, 2011
- New generation of drugs to cure hepatitis C - Aug 14, 2010
- How interferon-induced genes launch antiviral defenses - Apr 11, 2011
- Integrate Hepatitis C testing with HIV: NGOs - Oct 21, 2011
- Hepatitis C: Cure and control, right now! - Jul 29, 2010
- HIV replication process could be different than previously thought - Jul 16, 2010
- Molecule engineered to attack HIV shows positive results - Jan 20, 2011
- Complete structure of HIV's outer shell revealed - Jan 20, 2011
- Boffins approaching universal treatment for all influenza strains - Jun 05, 2010
Tags: donor screening, drug injections, hcv infections, hemodialysis patients, hepatitis c, hiv hcv, human pathogen, infectious virus, infectology, liver cancer, liver inflammation, liver scarring, long term goal, particle production, rna replication, scripps florida, sharing needles, virion, virus particle, virus reproduction